Lamivudine/Zidovudine Teva


lamivudine / zidovudine

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Lamivudine/Zidovudine Teva has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 21/03/2023

Authorisation details

Product details
Lamivudine/Zidovudine Teva
Agency product number
Active substance
  • lamivudine
  • zidovudine
International non-proprietary name (INN) or common name
  • lamivudine
  • zidovudine
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Teva Pharma B.V. 
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Teva Pharma B.V.
Swensweg 5
2031GA Haarlem
The Netherlands

Product information

21/03/2022 Lamivudine/Zidovudine Teva - EMEA/H/C/001236 - IB/0028

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.

Assessment history

How useful was this page?

Add your rating
2 ratings